1. Scalable Synthesis, in Vitro cccDNA Reduction, and in Vivo Antihepatitis B Virus Activity of a Phosphonomethoxydeoxythreosyl adenine Prodrug. Luo, M., S. Wu, R. Kalkeri, R.G. Ptak, T. Zhou, L. Van Mellaert, C. Wang, S.G. Dumbre, T. Block, E. Groaz, S. De Jonghe, Y. Li, and P. Herdewijn. Journal of Medicinal Chemistry, 2020. 63(22): p. 13851-13860. PMID[33191744].
[PubMed]. HBV_11_2020.
2. Discovery of Novel Quinazolinone Derivatives as Potential anti-HBV and anti-HCC Agents. Qiu, J., Q. Zhou, Y. Zhang, M. Guan, X. Li, Y. Zou, X. Huang, Y. Zhao, W. Chen, and X. Gu. European Journal of Medicinal Chemistry, 2020. 205: 112581. PMID[32791397].
[PubMed]. HBV_11_2020.
Patent Citations
3. Oxalamido-substituted Tricyclic Inhibitors of Hepatitis B Virus. De Francesco, R., L. Donnici, L. Guidotti, M. Iannacone, R. Di Fabio, V. Summa, A. Prandi, P. Randazzo, L. Ivanova Bencheva, M. De Matteo, L. Ferrante, D. Gornati, and A. Grillo. Patent. 2020. 2020-EP64424 2020234483.
[Patent]. HBV_11_2020.
4. Preparation of Amide Derivatives Useful in the Treatment of HBV Infection or HBV-Induced Diseases. Kesteleyn, B.R.R., J.M. Berke, E. Coesemans, S.C. Grosse, E. Jacoby, T.H.M. Jonckers, S.J. Last, W.G. Verschueren, M. Obringer, and C.C.C. Doebelin. Patent. 2020. 2020-EP62360 2020225230: 96pp.
[Patent]. HBV_11_2020.